Fulcrum Therapeutics Inc

Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company. The firm develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015 and is headquartered in Cambridge, MA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Fulcrum Therapeutics reports promising data and financial stability in Q4

Fulcrum Therapeutics showcased positive data for FTX-6058 and financial stability in their Q4 2022 earnings call
While facing challenges with the clinical hold, the company's strong cash position and promising programs offer opportunities for growth

Fulcrum Therapeutics reports solid financials, FDA challenges, and leadership change

Fulcrum Therapeutics navigates a mixed landscape with strong financials, promising clinical trial progress, and regulatory challenges that require careful resolution.
New leadership, ongoing FDA collaborations, and a robust cash position position Fulcrum for continued growth and innovation in the biopharmaceutical space.

Fulcrum Therapeutics reports stable finances, regulatory hurdles ahead

Fulcrum Therapeutics maintains a stable financial position with a focus on advancing key pipeline candidates.
Challenges include regulatory uncertainties for FTX-6058 and ongoing R&D investment impacting financials.
Opportunities lie in upcoming data releases, resolving regulatory issues, and strategic growth initiatives.

Fulcrum Therapeutics reports Q3 loss, progresses key clinical trials

Fulcrum Therapeutics reported a mixed performance in Q3 2023, with a net loss driven by significant R&D and administrative expenses.
Despite challenges in cash burn and timeline for commercialization, the company's strong cash position and promising clinical developments highlight its potential.
Opportunities lie in advancing regulatory filings, leveraging positive clinical results, and exploring additional endpoints to showcase therapy efficacy.

Fulcrum Therapeutics advances Phase III trials, secures strong financial position

Fulcrum Therapeutics made significant progress in advancing its pipeline with successful trial enrollments and resolution of clinical holds.
Financially, the company ended 2023 on a strong note with a healthy cash position and reported financials.
Challenges lie in meeting trial endpoints and managing expenses, but opportunities exist in market reception and further data collection.
Overall, Fulcrum's proactive approach to clinical development and stakeholder engagement positions it well for future growth.

Fulcrum Therapeutics secures Sanofi collaboration, advances Phase III trials

Fulcrum Therapeutics' collaboration with Sanofi and strong financial position provide a solid foundation for future growth and development.
The company's focus on advancing Phase III trials, addressing unmet medical needs, and driving innovation through novel endpoints positions it well for success.
While facing challenges in various operational aspects, Fulcrum's strategic planning and emphasis on key appointments and market access strategies indicate a proactive approach to overcoming obstacles.

Fulcrum Therapeutics reports strong Q2 earnings and advances clinical assets

Fulcrum Therapeutics achieved a significant turnaround in financial performance with a notable increase in net income and a strong cash position, supported by collaboration revenue.
Progress in Phase III trials for losmapimod and pociredir, along with positive patient engagement, bodes well for future drug development and market potential.
While facing regulatory and competitive challenges, the company's strategic collaborations, financial stability, and ongoing trials present opportunities for growth and market expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Fulcrum Therapeutics, Inc. (NASDAQ:FULC ) Q1 2022 Earnings Conference Call May 9, 2022 8:00 AM ET Company Participants Naomi Aoki - SVP, Corporate Communications & IR Bryan Stuart - President & CEO Judy Dunn - President, R&D Esther Rajavelu - CFO Chris Morabito - CMO Paul Bruno - Executive Director, Corporate Development Conference Call Participants Judah Frommer - Credit Suisse Dae Gon Ha - Stifel Ted Tenthoff - Piper Sandler Joseph Schwartz - SVB Matt Biegler - Oppenheimer Operator Good morning and welcome to Fulcrum Therapeutics' First Quarter 2022 Conference Call. Currently all participants are in a listen-only mode.

Fulcrum Therapeutics' (FULC) CEO Bryan Stuart on Q1 2022 Results - Earnings Call Transcript

– In itial data from Phase 1b trial of FTX-6058 in sickle cell disease to be presented at the EHA 2022 Congress –

Fulcrum Therapeutics Reports Recent Business Highlights and First Quarter 2022 Financial Results

CAMBRIDGE, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ®  (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will participate in a fireside chat at the BofA Securities 2022 Healthcare Conference, on Thursday, May 12, 2022 at 11:20 a.m. PT (2:20 p.m. ET).

Fulcrum Therapeutics to Participate at the Upcoming BofA Securities 2022 Healthcare Conference

Fulcrum Therapeutics, Inc. (FULC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

After Plunging 59.2% in 4 Weeks, Here's Why the Trend Might Reverse for Fulcrum Therapeutics, Inc. (FULC)

Fulcrum Therapeutics, Inc. (FULC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Fulcrum Therapeutics, Inc. (FULC) Q1 Earnings Expected to Decline

Investors need to pay close attention to Fulcrum (FULC) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Fulcrum (FULC) Stock?

Fulcrum Therapeutics, Inc. (FULC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Fulcrum Therapeutics, Inc. (FULC) Stock Jumps 5.7%: Will It Continue to Soar?

Presentations highlight potential of losmapimod to slow or stop progression of FSHD

Fulcrum Therapeutics® Announces Multiple Presentations on FSHD at the American Academy of Neurology's Annual Meeting

Event to discuss unmet need in FSHD, key measures of disease progression and Phase 3 REACH trial

Fulcrum Therapeutics® to Host Virtual Key Opinion Leader Webcast Featuring Losmapimod for Facioscapulohumeral Muscular Dystrophy (FSHD)

RWS has been correlated with ability to perform activities of daily living and maintain independence

Fulcrum Therapeutics® Presents Data Highlighting Reachable Workspace (RWS) as Relevant Functional Endpoint in Facioscapulohumeral Muscular Dystrophy (FSHD) at MDA Clinical and Scientific Conference

The average of price targets set by Wall Street analysts indicates a potential upside of 178.8% in Fulcrum Therapeutics, Inc. (FULC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Does Fulcrum Therapeutics, Inc. (FULC) Have the Potential to Rally 179% as Wall Street Analysts Expect?

Fulcrum Therapeutics, Inc.'s (FULC) CEO Bryan Stuart On Q4 2021 Results - Earnings Call Transcript

– Clear path forward for Phase 3 REACH trial with losmapimod in FSHD; Trial expected to begin in 2Q 2022 –

Fulcrum Therapeutics® Reports Recent Business Highlights and Fourth Quarter and Full Year 2021 Financial Results

The Phase 1b trial for the drug remains on track and will be initiated soon.

Fulcrum Therapeutics Latest Report On Its Sickle Cell Disease Trials

Fulcrum Therapeutics Inc (NASDAQ: FULC) has announced results from the 20mg and 30mg dose cohorts in healthy adult volunteers in its Phase 1 trial of FTX-6058 for sickle cell disease and other hemoglobinopathies, such as beta-thalassemia. The Company also shared new preclinical mechanism data showing that FTX-6058 downregulated known repressors of fetal hemoglobin (HbF).

Fulcrum Therapeutics Shares Additional Data From Phase 1 Trial Of Sickle Cell Disease Treatment

CAMBRIDGE, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.  (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced the appointment of Sonja L. Banks to the company's board of directors, effective December 8. Ms. Banks is currently the chief executive officer of the International Dyslexia Association and was formerly president of the Sickle Cell Disease Association of America (SCDAA). She brings nearly 25 years of experience in patient advocacy, community outreach and non-profit leadership, and she is deeply respected for her grassroots work in the rare disease and sickle cell disease communities.

Fulcrum Therapeutics® Appoints Sonja L. Banks to its Board of Directors

Fulcrum Therapeutics, Inc. (FULC) CEO Bryan Stuart on Q3 2021 results - Earnings Call Transcript

Fulcrum Therapeutics, Inc. (FULC) delivered earnings and revenue surprises of 10.94% and 68.03%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Fulcrum Therapeutics, Inc. (FULC) Reports Q3 Loss, Tops Revenue Estimates

–On-track to initiate enrollment by year-end in Phase 1b clinical trial of FTX-6058 in people with sickle cell disease–

Fulcrum Therapeutics® Reports Recent Business Highlights and Third Quarter 2021 Financial Results

CAMBRIDGE, Mass., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.  (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will be participating in the following upcoming investor conferences:

Fulcrum Therapeutics™ to Participate in Upcoming November Investor Conferences

CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.  (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that its third quarter 2021 financial results will be released on Thursday, November 4, 2021 before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide an update on recent corporate developments.

Fulcrum Therapeutics™ to Host Third Quarter 2021 Financial Results Conference Call and Webcast on Thursday, November 4, 2021 at 8:00 a.m. ET

The consensus price target hints at a 30.9% upside potential for Fulcrum Therapeutics, Inc. (FULC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Can Fulcrum Therapeutics, Inc. (FULC) Climb 31% to Reach the Level Wall Street Analysts Expect?

CAMBRIDGE, Mass., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced the grant of an inducement award outside of the Company's 2019 Stock Incentive Plan to Naomi Aoki, the Company's newly appointed SVP, Communications and Investor Relations. The grant was approved by the Compensation Committee on September 10, 2021, as an inducement material to the employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

Fulcrum Therapeutics™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

– Presentations highlight progress in the development of losmapimod for FSHD –

Fulcrum Therapeutics™ Announces Multiple Presentations During the Virtual Congress of the World Muscle Society

FULC has multiple interesting programs with decent data.

News for Fulcrum Therapeutics Inc Stock (FULC)